Posted by Michael Wonder on 12 Mar 2020
Around 10,000 people could benefit from new migraine drug as NICE says it’s cost-effective
12 March 2020 - NICE has today published final draft guidance which recommends fremanezumab (also called Ajovy and made by Teva Pharmaceuticals) for preventing chronic migraine.
The draft guidance recommends fremanezumab for preventing chronic migraine in adults where at least 3 previous preventive treatments have failed, opening the way for up to 10,000 people to receive it on the NHS in England.
The clinical trial evidence shows that fremanezumab works better than best supportive care (which usually consists of acute treatments for migraine symptoms) for preventing chronic migraine in people who have already tried 3 preventive treatments.
